Villasis, Leavie .
HRN: 21-78-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/16/2022
CEFUROXIME 500MG (TAB)
08/16/2022
08/22/2022
PO
500mg
BID
S/P NSVD, With Laceration And Repair
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes